MRI radiomics for the prediction of recurrence in patients with clinically non-functioning pituitary macroadenomas

被引:33
|
作者
Machado, Leonardo F. [1 ]
Elias, Paula C. L. [3 ]
Moreira, Ayrton C. [3 ]
dos Santos, Antonio C. [4 ]
Murta Junior, Luiz O. [1 ,2 ]
机构
[1] Univ Sao Paulo, Dept Phys, Fac Philosophy Sci & Letters Ribeirao Preto, Ribeirao Preto, SP, Brazil
[2] Univ Sao Paulo, Dept Comp & Math, Fac Philosophy Sci & Letters Ribeirao Preto, Ribeirao Preto, SP, Brazil
[3] Univ Sao Paulo, Clin Hosp, Fac Med Ribeirao Preto, Endocrinol Div, Ribeirao Preto, SP, Brazil
[4] Univ Sao Paulo, Clin Hosp, Fac Med Ribeirao Preto, Endocrinol Div,Ctr Image Sci & Med Phys, Ribeirao Preto, SP, Brazil
关键词
Radiomics; MRI; Pituitary adenoma; Tumor recurrence; Machine learning; TEXTURE ANALYSIS; ADENOMAS; CLASSIFICATION; RADIOTHERAPY; MANAGEMENT; FEATURES; TUMORS; DIAGNOSIS; PATTERN; KI-67;
D O I
10.1016/j.compbiomed.2020.103966
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Twelve to 66% of patients with clinically non-functioning pituitary adenoma (NFPA) experience tumor recurrence 1-5 years after the first surgery. Nevertheless, there is still no recurrence prediction factor concisely established and reproduced in the literature for NFPA management. The present study evaluates the prognostic value of MRI Radiomics features combined with machine learning models to assess recurrence after the first surgery in patients with clinically non-functioning pituitary adenomas (NFPA). We carried out a retrospective study on 27 patients with NFPA, 10 patients having experienced tumor recurrence after the first surgery and 17 who did not. Preoperative 3D T-1 contrast-enhanced MR images of patients were used to extract up to 255 Radiomics features from two and three-dimensional segmented regions. Additionally, gender, age at first surgery, and the presence of remnant tumor tissue were investigated to find the correlation with NFPA recurrence. Conventional statistics tests were used to evaluate whether the outcome patient groups (stable and recurrent) were different considering each feature individually. Additionally, five well-known machine-learning algorithms were used in combination with Radiomic features to classify recurrent and stable lesions. We found statistical evidence (p < 0.02) for 6 two-dimensional and 13 three-dimensional radiomic features. We achieved accuracies of up to 96.3% for 3D-feature based models and up to 92.6% accuracies for 2D-feature based models. 3D-feature based models achieved better performances using considerably fewer features when compared to 2D-feature based models. We concluded that Radiomics have the potential of NFPA recurrence prediction after the first surgery. Three-dimensional Radiomics have superior discrimination power to predict NFPA recurrence than two-dimensional radiomic features. Finally, the combination of Radiomics with machine-learning algorithms can offer computational models capable of non-invasive, unbiased, and quick assessment that might improve the prediction of NFPA recurrence.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Current concepts and controversies in the management of non-functioning giant pituitary macroadenomas
    Agrawal, Amit
    Cincu, Rafael
    Goel, Atul
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2007, 109 (08) : 645 - 650
  • [22] The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)
    Yavropoulou, Maria P.
    Tsoli, Marina
    Barkas, Konstantinos
    Kaltsas, Gregory
    Grossman, Ashley
    ENDOCRINE-RELATED CANCER, 2020, 27 (10) : R375 - R390
  • [23] Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas
    Karamouzis, I.
    Berardelli, R.
    Prencipe, N.
    Berton, A.
    Bona, C.
    Stura, G.
    Corsico, M.
    Gasco, V.
    Maccario, M.
    Ghigo, E.
    Grottoli, S.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2015, 38 (11): : 1191 - 1197
  • [24] Baseline MRI findings as predictors of hypopituitarism in patients with non-functioning pituitary adenomas
    Al Argan, Reem
    Ramadhan, Abdulaziz
    Agnihotram, Ramanakumar, V
    Chankowsky, Jeffrey
    Rivera, Juan
    ENDOCRINE CONNECTIONS, 2021, 10 (11) : 1445 - 1454
  • [25] Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas
    Rui, Wenting
    Qiao, Nidan
    Wu, Yue
    Zhang, Yong
    Aili, Ababikere
    Zhang, Zhaoyun
    Ye, Hongying
    Wang, Yongfei
    Zhao, Yao
    Yao, Zhenwei
    EUROPEAN RADIOLOGY, 2022, 32 (03) : 1570 - 1578
  • [26] Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas
    Cannavo, S.
    Ferrau, F.
    Cotta, O. R.
    Saitta, S.
    Barresi, V.
    Cristani, M. T.
    Saija, A.
    Ruggeri, R. M.
    Trimarchi, F.
    Gangemi, S.
    PITUITARY, 2014, 17 (01) : 76 - 80
  • [27] MiRNA Signatures Related to Invasiveness and Recurrence in Patients With Non-Functioning Pituitary Neuroendocrine Tumors
    Nikolova, Emiliya
    Nankova, Anelia
    Kalenderova, Silvia
    Georgieva, Bilyana
    Hadzhiyanev, Asen
    Bichev, Stoyan
    Savov, Alexey
    Todorova, Albena
    Mitev, Vanyo
    Elenkova, Atanaska
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2024, 132 (05) : 240 - 248
  • [28] Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma
    Crouzeix, Genevieve
    Morello, Remy
    Thariat, Juliette
    Morera, Julia
    Joubert, Michael
    Reznik, Yves
    HORMONE AND METABOLIC RESEARCH, 2019, 51 (03) : 178 - 185
  • [29] Alpha subunit in clinically non-functioning pituitary adenomas: An immunohistochemical study
    Solarski, Michael
    Rotondo, Fabio
    Syro, Luis V.
    Cusimano, Michael D.
    Kovacs, Kalman
    PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (09) : 1130 - 1133
  • [30] Intraoperative MRI and endocrinological outcome of transsphenoidal surgery for non-functioning pituitary adenoma
    Berkmann, Sven
    Fandino, Javier
    Mueller, Beat
    Remonda, Luca
    Landolt, Hans
    ACTA NEUROCHIRURGICA, 2012, 154 (04) : 639 - 647